1023652-41-6Relevant academic research and scientific papers
Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors
Huang, Xiaohua,Cheng, Cliff C.,Fischmann, Thierry O.,Duca, José S.,Richards, Matthew,Tadikonda, Praveen K.,Reddy, Panduranga Adulla,Zhao, Lianyun,Arshad Siddiqui,Parry, David,Davis, Nicole,Seghezzi, Wolfgang,Wiswell, Derek,Shipps Jr., Gerald W.
, p. 2590 - 2594 (2013/06/27)
Drug design efforts in the emerging 2-aminothiazole-4-carboxamide class of CHK1 inhibitors have uncovered specific combinations of key substructures within the molecule; resulting in significant improvements in cell-based activity while retaining a greater than one hundred-fold selectivity against CDK2. The X-ray crystal structure of a complex between compound 39 and the CHK1 protein detailing a 'U-shaped' topology and key interactions with the protein surface at the ATP site is also reported.
2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS
-
Page/Page column 81, (2008/12/05)
The present invention relates to novel Anilinopiperazine Derivatives of formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase.
